Literature DB >> 23183138

Long-term anticholinergic use and the aging brain.

Xueya Cai1, Noll Campbell, Babar Khan, Christopher Callahan, Malaz Boustani.   

Abstract

BACKGROUND: Older Americans are facing an epidemic of chronic diseases and are thus exposed to anticholinergics (ACs) that might negatively affect their risk of developing mild cognitive impairment (MCI) or dementia.
OBJECTIVE: To investigate the association between impairment in cognitive function and previous AC exposure.
DESIGN: A retrospective cohort study.
SETTING: Primary care clinics in Indianapolis, Indiana. PARTICIPANTS: A total of 3690 older adults who have undergone cognitive assessment and had a 1-year medication-dispensing record. OUTCOME: Cognitive function was measured in two sequential steps: a two-step screening process followed by a formal diagnostic process for participants with positive screening results. EXPOSURE: Three patterns of AC exposure were defined by the duration of AC exposure, the number of AC medications dispensed at the same time, and the severity of AC effects as determined by the Anticholinergic Cognitive Burden list.
RESULTS: Compared with older adults with no AC exposure and after adjusting for age, race, gender, and underlying comorbidity, the odds ratio for having a diagnosis of MCI was 2.73 (95% confidence interval, 1.27-5.87) among older adults who were exposed to at least three possible ACs for at least 90 days; the odds ratio for having dementia was 0.43 (95% confidence interval, 0.10-1.81).
CONCLUSION: Exposure to medications with severe AC cognitive burden may be a risk factor for developing MCI.
Copyright © 2013 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23183138      PMCID: PMC3674201          DOI: 10.1016/j.jalz.2012.02.005

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN: 1552-5260            Impact factor:   21.566


  26 in total

1.  A chronic disease score from automated pharmacy data.

Authors:  M Von Korff; E H Wagner; K Saunders
Journal:  J Clin Epidemiol       Date:  1992-02       Impact factor: 6.437

2.  M1 receptors play a central role in modulating AD-like pathology in transgenic mice.

Authors:  Antonella Caccamo; Salvatore Oddo; Lauren M Billings; Kim N Green; Hilda Martinez-Coria; Abraham Fisher; Frank M LaFerla
Journal:  Neuron       Date:  2006-03-02       Impact factor: 17.173

3.  Validation of patient reports, automated pharmacy records, and pill counts with electronic monitoring of adherence to antihypertensive therapy.

Authors:  P W Choo; C S Rand; T S Inui; M L Lee; E Cain; M Cordeiro-Breault; C Canning; R Platt
Journal:  Med Care       Date:  1999-09       Impact factor: 2.983

4.  Who refuses the diagnostic assessment for dementia in primary care?

Authors:  Malaz Boustani; Anthony J Perkins; Chris Fox; Fred Unverzagt; Mary Guerriero Austrom; Bridget Fultz; Siu Hui; Christopher M Callahan; Hugh C Hendrie
Journal:  Int J Geriatr Psychiatry       Date:  2006-06       Impact factor: 3.485

5.  Association between medication supplies and healthcare costs in older adults from an urban healthcare system.

Authors:  K T Stroupe; M D Murray; T E Stump; C M Callahan
Journal:  J Am Geriatr Soc       Date:  2000-07       Impact factor: 5.562

6.  Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: longitudinal cohort study.

Authors:  Marie L Ancelin; Sylvaine Artero; Florence Portet; Anne-Marie Dupuy; Jacques Touchon; Karen Ritchie
Journal:  BMJ       Date:  2006-02-01

7.  Use of anticholinergic medications by older adults with dementia.

Authors:  Catherine M Roe; Michael J Anderson; Barney Spivack
Journal:  J Am Geriatr Soc       Date:  2002-05       Impact factor: 5.562

8.  Lowering the risk of Alzheimer's disease: evidence-based practices emerge from new research.

Authors:  M Kathryn Jedrziewski; Virginia M-Y Lee; John Q Trojanowski
Journal:  Alzheimers Dement       Date:  2005-10       Impact factor: 21.566

9.  Six-item screener to identify cognitive impairment among potential subjects for clinical research.

Authors:  Christopher M Callahan; Frederick W Unverzagt; Siu L Hui; Anthony J Perkins; Hugh C Hendrie
Journal:  Med Care       Date:  2002-09       Impact factor: 2.983

Review 10.  The cognitive impact of anticholinergics: a clinical review.

Authors:  Noll Campbell; Malaz Boustani; Tony Limbil; Carol Ott; Chris Fox; Ian Maidment; Cathy C Schubert; Stephanie Munger; Donna Fick; David Miller; Rajesh Gulati
Journal:  Clin Interv Aging       Date:  2009-06-09       Impact factor: 4.458

View more
  54 in total

1.  Muscarinic Receptor M3R Signaling Prevents Efficient Remyelination by Human and Mouse Oligodendrocyte Progenitor Cells.

Authors:  R Ross Welliver; Jessie J Polanco; Richard A Seidman; Anjali K Sinha; Melanie A O'Bara; Zainab M Khaku; Diara A Santiago González; Akiko Nishiyama; Jurgen Wess; M Laura Feltri; Pablo M Paez; Fraser J Sim
Journal:  J Neurosci       Date:  2018-06-29       Impact factor: 6.167

2.  Relationship Between African-American Race and Delirium in the ICU.

Authors:  Babar A Khan; Anthony Perkins; Siu L Hui; Sujuan Gao; Noll L Campbell; Mark O Farber; Malaz A Boustani
Journal:  Crit Care Med       Date:  2016-09       Impact factor: 7.598

3.  Proton Pump Inhibitors and Risk of Mild Cognitive Impairment and Dementia.

Authors:  Felicia C Goldstein; Kyle Steenland; Liping Zhao; Whitney Wharton; Allan I Levey; Ihab Hajjar
Journal:  J Am Geriatr Soc       Date:  2017-06-07       Impact factor: 5.562

Review 4.  Anticholinergic medication use and dementia: latest evidence and clinical implications.

Authors:  Shelly L Gray; Joseph T Hanlon
Journal:  Ther Adv Drug Saf       Date:  2016-07-18

5.  Association between anticholinergic (atropinic) drug exposure and cognitive function in longitudinal studies among individuals over 50 years old: a systematic review.

Authors:  Laurine Andre; Adeline Gallini; François Montastruc; Jean-Louis Montastruc; Antoine Piau; Maryse Lapeyre-Mestre; Virginie Gardette
Journal:  Eur J Clin Pharmacol       Date:  2019-08-29       Impact factor: 2.953

6.  Comparative Associations Between Measures of Anti-cholinergic Burden and Adverse Clinical Outcomes.

Authors:  Wen-Han Hsu; Yu-Wen Wen; Liang-Kung Chen; Fei-Yuan Hsiao
Journal:  Ann Fam Med       Date:  2017-11       Impact factor: 5.166

Review 7.  Impact of anticholinergic discontinuation on cognitive outcomes in older people: a systematic review.

Authors:  Mohammed Saji Salahudeen; Stephen B Duffull; Prasad S Nishtala
Journal:  Drugs Aging       Date:  2014-03       Impact factor: 3.923

8.  Association Between Anticholinergic Medication Use and Cognition, Brain Metabolism, and Brain Atrophy in Cognitively Normal Older Adults.

Authors:  Shannon L Risacher; Brenna C McDonald; Eileen F Tallman; John D West; Martin R Farlow; Fredrick W Unverzagt; Sujuan Gao; Malaz Boustani; Paul K Crane; Ronald C Petersen; Clifford R Jack; William J Jagust; Paul S Aisen; Michael W Weiner; Andrew J Saykin
Journal:  JAMA Neurol       Date:  2016-06-01       Impact factor: 18.302

9.  Adverse cognitive effects of medications: turning attention to reversibility.

Authors:  Noll L Campbell; Malaz A Boustani
Journal:  JAMA Intern Med       Date:  2015-03       Impact factor: 21.873

10.  [Delirium: an interdisciplinary challenge].

Authors:  T Frühwald; M Weissenberger-Leduc; C Jagsch; K Singler; S Gurlit; W Hofmann; B Böhmdorfer; B Iglseder
Journal:  Z Gerontol Geriatr       Date:  2014-07       Impact factor: 1.281

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.